Patents by Inventor Thomas Allen Ceska
Thomas Allen Ceska has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250011473Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the Fc?RI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the C?2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the C?2 domain of IgE) and/or the ability to disassociate IgE from the Fc?RI receptor for instance at pharmaceutically-relevant concentrations.Type: ApplicationFiled: June 26, 2024Publication date: January 9, 2025Inventors: Ralph ADAMS, Thomas Allen CESKA, Anna Marie DAVIES, Alistair James HENRY, Xiaofeng LIU, James Michael MCDONNELL, Brian John SUTTON, Marta Katarzyna WESTWOOD
-
Patent number: 12054559Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the Fc?RI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the C?2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the C?2 domain of IgE) and/or the ability to disassociate IgE from the Fc?RI receptor for instance at pharmaceutically-relevant concentrations.Type: GrantFiled: December 3, 2021Date of Patent: August 6, 2024Assignee: UCB BIOPHARMA SRLInventors: Ralph Adams, Thomas Allen Ceska, Anna Marie Davies, Alistair James Henry, Xiaofeng Liu, James Michael McDonnell, Brian John Sutton, Marta Katarzyna Westwood
-
Publication number: 20220235146Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the Fc?RI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the C?2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the C?2 domain of IgE) and/or the ability to disassociate IgE from the Fc?RI receptor for instance at pharmaceutically-relevant concentrations.Type: ApplicationFiled: December 3, 2021Publication date: July 28, 2022Inventors: Ralph ADAMS, Thomas Allen CESKA, Anna Marie DAVIES, Alistair James HENRY, Xiaofeng LIU, James Michael MCDONNELL, Brian John SUTTON, Marta Katarzyna WESTWOOD
-
Publication number: 20220162311Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.Type: ApplicationFiled: December 9, 2021Publication date: May 26, 2022Applicant: UCB BIOPHARMA SPRLInventors: Paul Alan ATHERFOLD, Thomas Allen CESKA, Helene Margaret FINNEY, Lara KEVORKIAN, Kaushik SARKAR, Bryan John SMITH, Kerry Louise TYSON
-
Patent number: 11220547Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.Type: GrantFiled: March 12, 2019Date of Patent: January 11, 2022Assignee: UCB Biopharma SPRLInventors: Paul Alan Atherfold, Thomas Allen Ceska, Helene Margaret Finney, Lara Kevorkian, Kaushik Sarkar, Bryan John Smith, Kerry Louise Tyson
-
Patent number: 11214627Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the Fc?RI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the C?2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the C?2 domain of IgE) and/or the ability to disassociate IgE from the Fc?RI receptor for instance at pharmaceutically-relevant concentrations.Type: GrantFiled: June 8, 2017Date of Patent: January 4, 2022Assignee: UCB BIOPHARMA SRLInventors: Ralph Adams, Thomas Allen Ceska, Anna Marie Davies, Alistair James Henry, Xiaofeng Liu, James Michael McDonnell, Brian John Sutton, Marta Katarzyna Westwood
-
Publication number: 20190270811Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.Type: ApplicationFiled: March 12, 2019Publication date: September 5, 2019Inventors: Paul Alan ATHERFOLD, Thomas Allen CESKA, Helene Margaret FINNEY, Lara KEVORKIAN, Kaushik SARKAR, Bryan John SMITH, Kerry Louise TYSON
-
Publication number: 20190144565Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the Fc?RI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the C?2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the C?2 domain of IgE) and/or the ability to disassociate IgE from the Fc?RI receptor for instance at pharmaceutically-relevant concentrations.Type: ApplicationFiled: June 8, 2017Publication date: May 16, 2019Inventors: Ralph ADAMS, Thomas Allen CESKA, Anna Marie DAVIES, Alistair James HENRY, Xiaofeng LIU, James Michael MCDONNELL, Brian John SUTTON, Marta Katarzyna WESTWOOD
-
Patent number: 10273302Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.Type: GrantFiled: November 12, 2014Date of Patent: April 30, 2019Assignee: UCB Biopharma SPRLInventors: Paul Alan Atherfold, Thomas Allen Ceska, Helene Margaret Finney, Lara Kevorkian, Kaushik Sarkar, Bryan John Smith, Kerry Louise Tyson
-
Publication number: 20180037646Abstract: The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.Type: ApplicationFiled: September 7, 2017Publication date: February 8, 2018Applicant: UCB BIOPHARMA SPRLInventors: Thomas Allen Ceska, Alistair James Henry, Jiye Shi
-
Patent number: 9771420Abstract: The present invention relates neutralizing epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.Type: GrantFiled: June 29, 2015Date of Patent: September 26, 2017Assignee: UCB BIOPHARMA SPRLInventors: Thomas Allen Ceska, Alistar James Henry, Jiye Shi
-
Publication number: 20160264668Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.Type: ApplicationFiled: November 12, 2014Publication date: September 15, 2016Inventors: Paul Alan ATHERFOLD, Thomas Allen CESKA, Helene Margaret FINNEY, Lara KEVORKIAN, Kaushik SARKAR, Bryan John SMITH, Kerry Louise TYSON
-
Publication number: 20150315272Abstract: The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.Type: ApplicationFiled: June 29, 2015Publication date: November 5, 2015Inventors: Thomas Allen Ceska, Alistar James Henry, Jiye Shi
-
Patent number: 9045537Abstract: The present invention relates neutralizing epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.Type: GrantFiled: February 5, 2014Date of Patent: June 2, 2015Assignee: UCB PHARMA SAInventors: Thomas Allen Ceska, Alistar James Henry, Jiye Shi
-
Publication number: 20140193403Abstract: The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.Type: ApplicationFiled: February 5, 2014Publication date: July 10, 2014Applicant: UCB Pharma S.A.Inventors: Thomas Allen Ceska, Alistar James Henry, Jiye Shi
-
Patent number: 8679494Abstract: The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.Type: GrantFiled: April 22, 2009Date of Patent: March 25, 2014Assignee: UCB Pharma S.A.Inventors: Thomas Allen Ceska, Alistair James Henry
-
Publication number: 20110262443Abstract: The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.Type: ApplicationFiled: April 22, 2009Publication date: October 27, 2011Applicant: UCB PHARMA S.A.Inventors: Thomas Allen Ceska, Alistair James Henry, Jiye Shi